5 Results for "

endostatin

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "endostatin" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-P1263A
CAS No.: 1262750-73-1
Synonyms: (trans-Cinnamoyl)-YPGKF-NH2 TFA
tcY-NH2 ((trans-Cinnamoyl)-YPGKF-NH2) TFA is a potent selective PAR4 antagonist peptide. tcY-NH2 TFA inhibits thrombin- and AY-NH2-induced platelet aggregation and endostatin release, and can be used in the research of inflammation, immunology .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P1263
CAS No.: 327177-34-4
Synonyms: (trans-Cinnamoyl)-YPGKF-NH2
tcY-NH2 ((trans-Cinnamoyl)-YPGKF-NH2) is a potent selective PAR4 antagonist peptide. tcY-NH2 inhibits thrombin- and AY-NH2-induced platelet aggregation and endostatin release, and can be used in the research of inflammation, immunology .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P7009
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rHuendostatin; Collagen alpha-1(XV) chain
Species:  
Source:  
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P70347
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rMuCollagen Alpha-1(XVIII) Chain/endostatin, His; antiangiogenic agent; COL18A1; collagen alpha-1(XVIII)chain; collagen; type XVIII; endostatin
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-L088
3,577 compounds

Angiogenesis is the physiological process through which new blood vessels are formed from pre-existing vessels. It occurs in various physiological processes e.g. embryonic development, menstrual cycle, exercise and wound healing etc. Angiogenesis is regulated by both endogenous activators and inhibitors. Some key activators of angiogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, TGF-β, etc. whereas angiogenesis inhibitors are angiostatin, endostatin, interferon, platelet factor 4, etc. The loss of balance between these opposing signals leads to life threatening diseases like cancer, cardiovascular and ischemic diseases etc. which are thus controlled by exogenous angiogenesis activators (for cardiovascular/ischemic disorders) and inhibitors (for cancer).

MCE offers a unique collection of 3,577 compounds with validated angiogenesis targets modulating properties. MCE angiogenesis-related compound library is an effective tool for angiogenesis research and discovery of angiogenesis-related drugs.